Soliris (eculizumab) / AstraZeneca 
Welcome,         Profile    Billing    Logout  
 85 Diseases   26 Trials   26 Trials   4615 News 


«12...4647484950515253545556...5758»
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma
    Journal:  Optimal management of atypical hemolytic uremic disease: challenges and solutions. (Pubmed Central) -  Oct 1, 2019   
    Limited data on the natural history of aHUS along with the underlying genetic mutations make it difficult to predict the relapses and thereby raising concerns about the appropriate duration and monitoring of treatment. In this review, we discuss the safety and efficacy of eculizumab in patients with aHUS and its associated challenges.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma
    Clinical, Journal:  Combined and sequential liver-kidney transplantation in children. (Pubmed Central) -  Sep 30, 2019   
    Availability of anti-C5a antibody (eculizumab) has limited the validity of CLKT in genetic atypical hemolytic uremic syndrome (aHUS)...No such protection is observed in SLKT, when both organs come from different donors, except uncommon cases of living donation of both organs. Overall long-term outcome in CLKT in terms of graft survival is good and not different from isolated liver or kidney transplantation, however patient survival is inferior due to complexity of this procedure.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma
    Clinical, Journal:  Atypical Hemolytic Uremic Syndrome in Children Aged <2 Years. (Pubmed Central) -  Sep 30, 2019   
    One-third of the aHUS patients had disease onset during infancy. The prognosis of this life-threatening disease seems to get better with improved treatment modalities.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma
    Clinical, Journal:  Extra-Renal manifestations of atypical hemolytic uremic syndrome in children. (Pubmed Central) -  Sep 30, 2019   
    Thus, prospective, controlled trials should be undertaken. The most common and serious extrarenal manifestation of aHUS is neurological involvement and treatment outcome findings presented herein are important to all relevant clinicians.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma
    Journal:  The impact of eculizumab on routine complement assays. (Pubmed Central) -  Sep 28, 2019   
    CH50, AH50 or C5 function assays can serve as indicators for the pharmacodynamic effects of eculizumab. Allied to ECU concentration, laboratory studies may be helpful to tailor therapy.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma
    Review, Journal:  The effect on the immunology laboratory of the expansion in complement therapeutics. (Pubmed Central) -  Sep 28, 2019   
    The approval in the US and Europe of Eculizumab in 2007 marked a change in complement therapeutics, and with it the landscape for complement testing in the clinical immunology laboratory changed...Every pathway and about every component of complement has been targeted by these drug development programs, and the modalities of the drugs in development are diverse. These developments will likely result in more laboratories offering more complement testing, so this review looks forward to some of those possible changes in testing.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma
    'I DID NOT EAT ANY HAMBURGER': A CASE OF ATYPICAL HEMOLYTIC UREMIC SYNDROME (Ernest N. Morial Convention Center - Exhibit Hall - Poster Area 5) -  Sep 25, 2019 - Abstract #CHEST2019CHEST_3585;    
    Physicians should be aware of the potential aHUS with the use of gemcitabine that may present with hemolysis, acute renal insufficiency and thrombocytopenia. Prompt stoppage of the drug, dialysis and eculizumab (monoclonal antibody against complement protein C5) can be used to treat this microtic angiopathy.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma
    MUCORMYCOSIS AND CANDIDEMIA FOLLOWING ECULIZUMAB TREATMENT FOR ATYPICAL HEMOLYTIC UREMIC SYNDROME (Ernest N. Morial Convention Center - Exhibit Hall - Poster Area 4) -  Sep 25, 2019 - Abstract #CHEST2019CHEST_2416;    
    Prompt stoppage of the drug, dialysis and eculizumab (monoclonal antibody against complement protein C5) can be used to treat this microtic angiopathy. Until there is more data on the full impact of terminal complement inhibition, practitioners should be highly vigilant in monitoring patients on eculizumab for infections beyond those caused by encapsulated organisms.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma
    A CASE OF DISSEMINATED NOCARDIA INFECTION IN AN ADULT WITH PANCYTOPENIA (Ernest N. Morial Convention Center - Exhibit Hall - Poster Area 2) -  Sep 25, 2019 - Abstract #CHEST2019CHEST_1651;    
    Failure of early detection and aggressive treatment can result in dissemination of the bacteria. Nocardia may have an indolent presentation and detection may be challenging, but with the risk factors and soil exposure taken into account, it should be considered a differential to help avoid significant morbidity and mortality.
  • ||||||||||  Soliris (eculizumab) / AstraZeneca
    New P1 trial:  The Use of Eculizumab in HELLP Syndrome (clinicaltrials.gov) -  Sep 24, 2019   
    P1,  N=15, Not yet recruiting, 
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma
    Review, Journal:  Human genetics in atypical hemolytic uremic syndrome-its role in diagnosis and treatment (Pubmed Central) -  Sep 22, 2019   
    Although genetics are not required for the diagnosis of aHUS, it is of great importance for the decision on how long to treat with the C5 inhibitor eculizumab. Also, knowledge of genetic alterations is absolutely essential if a living related donor is considered, in order to protect the living donor and recipient from developing aHUS.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma, Ultomiris IV (ravulizumab IV) / Alexion Pharma
    Review, Journal:  Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria. (Pubmed Central) -  Sep 21, 2019   
    In two recently published phase III non-inferiority trials, ravulizumab was found to be non-inferior to eculizumab both in efficacy and safety for the treatment of patients with PNH. Based on these results, ravulizumab was approved by the US FDA on 21 December 2018 and is currently under regulatory review in both the European Union and Japan.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma, Rituxan (rituximab) / Roche, Biogen
    Journal:  Thrombotic microangiopathy following haematopoietic stem cell transplant. (Pubmed Central) -  Sep 18, 2019   
    In severe cases, complement inhibitors such as eculizumab may play a valuable role. Further research is required to define the pathophysiology and determine both robust diagnostic criteria and the optimal treatment.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma
    Review, Journal:  Novel insights into the treatment of complement-mediated hemolytic anemias. (Pubmed Central) -  Sep 17, 2019   
    Upstream complement modulation is currently being investigated and appears to be a highly promising therapy, and two such agents have entered phase II and III trials. Of these, the anti-C1s monoclonal antibody sutimlimab has shown favorable activity in CAD, while the anti-C3 cyclic peptide pegcetacoplan appears to be promising in PNH as well as CAD, and may also have a therapeutic potential in wAIHA.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma
    Clinical, Journal:  C5b9 Formation on Endothelial Cells Reflects Complement Defects among Patients with Renal Thrombotic Microangiopathy and Severe Hypertension. (Pubmed Central) -  Sep 16, 2019   
    Eculizumab improved the renal function in three patients and prevented TMA recurrence in an allograft recipient.Conclusions These observations point to complement defects as the key causative factor of ESRD and recurrent TMA after transplant in patients presenting with severe hypertension. Complement defects can be identified by measurements of complement activation on microvascular endothelial cells, which should substantially influence treatment and prognosis.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma
    Journal:  Atypical Presentation of Pregnancy-Related Hemolytic Uremic Syndrome. (Pubmed Central) -  Sep 7, 2019   
    We focus on diagnostic challenges, especially because many patients with TMA do not present with thrombocytopenia, which can delay diagnosis. We additionally review the clinical settings in which administration of eculizumab, a C5 membrane attack complex inhibitor, is appropriate.
  • ||||||||||  melphalan / Generic mfg., Soliris (eculizumab) / Alexion Pharma, etoposide IV / Generic mfg.
    Clinical, Journal:  High-dose Carboplatin/Etoposide/Melphalan increases risk of thrombotic microangiopathy and organ injury after autologous stem cell transplantation in patients with neuroblastoma. (Pubmed Central) -  Sep 7, 2019   
    Sixty patients underwent aHCT using high-dose chemotherapy: 41 patients received carboplatin/etoposide/melphalan (CEM), 13 patients busulfan/melphalan (Bu/Mel) and six patients received tandem transplant (cyclophosphamide/thiotepa and CEM)...Out of seven patients who did not get eculizumab, two died from TA-TMA complications and four progressed to ESRD. We conclude that the CEM regimen is associated with a high incidence of clinically significant TA-TMA after aHCT and eculizumab can be safe and effective treatment option to remediate TA-TMA associated MOF.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma
    Journal:  Pharmaceutical Approval Update. (Pubmed Central) -  Sep 6, 2019   
    We conclude that the CEM regimen is associated with a high incidence of clinically significant TA-TMA after aHCT and eculizumab can be safe and effective treatment option to remediate TA-TMA associated MOF. Alpelisib (Piqray) for HR-positive/HER2-negative, PIK3CA-mutated, advanced/ metastatic breast cancer; polatuzumab vedotin-piiq (Polivy) for diffuse large B-cell lymphoma; and eculizumab (Soliris) for neuromyelitis optica spectrum disorder.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma, Rituxan (rituximab) / Roche, Biogen
    Review, Journal:  Thrombosis and Anti-phospholipid Syndrome: a 5-Year Update on Treatment. (Pubmed Central) -  Sep 4, 2019   
    Despite adequate treatment, APS patients display a significant rate of recurrences; rituximab, eculizumab, and intravenous immunoglobulins are among the options to be considered for these patients. From 2013 to date, the kaleidoscope of therapeutic options in thrombotic APS has been enriched, but tangible improvements in the management of patients are still awaited.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma, Rituxan (rituximab) / Roche, Biogen
    Clinical, Journal:  Refractory Thrombotic Thrombocytopenic Purpura in a patient with Kaposi sarcoma. (Pubmed Central) -  Aug 30, 2019   
    Novel treatment agents consisting of bortezomib and eculizumab given to the patient were also ineffective. To the best of our knowledge, this case presents the first case of coexistence of TTP and Kaposi sarcoma from Turkey and the challenge of refractory TTP management.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma
    Review, Journal:  Treatment of Myasthenia Gravis. (Pubmed Central) -  Aug 30, 2019   
    Nearly all of the drugs used for MG are considered "off-label." The 2 exceptions are acetylcholinesterase inhibitors and complement inhibition with eculizumab, which was recently approved by the US Food and Drug Administration for myasthenia gravis. This article reviews the evidence base and provides a framework for the treatment of myasthenia gravis, highlighting recent additions to the literature.